GUERBET : 1st quarter 2017 revenue
April 27 2017 - 11:48AM
€197.3 million at constant exchange rates, up
7.4%
Confirmation of the trend that started in the
fourth quarter of 2016
Villepinte, April 27, 2017 -
Guerbet (FR0000032526 GBT), a global specialist in contrast
agents and solutions for medical imaging, is publishing revenue of
€203.1 million for the 1st quarter of 2017, up by 10.5% at current
exchange rates (7.4% at constant exchange rates) compared with the
same period last year.
Consolidated Group revenue (IFRS)
In millions of euros at
March 31, 2017 |
Change
(%) |
2017at current exchange rates
|
Change
(%) |
2017at constant exchange rates
|
2016 |
Sales in Europe |
+1.1% |
94.3 |
+2.2% |
95.3 |
93.2 |
Sales in Other Markets |
+20.3% |
108.8 |
+12.7% |
102.0 |
90.5 |
Total 1st quarter revenue |
+10.5% |
203.1 |
+7.4% |
197.3 |
183.7 |
Activity is growing in Europe and in the Other
Markets. The 1st quarter 2017 revenue in Europe totaled €95.3
million, up 2.2% at constant exchange rates, given the now
effective prioritization of product/market pairings (for X-rays in
particular). Sales are still growing strongly in the Other Markets,
especially in Asia, a priority development zone for the Group, as
well as in the US and Latin America, and particularly Brazil.
At constant exchange rates, activity grew in
every segment:
- The MRI segment reported revenue of €65.6 million,
representing a 10.4% increase, thanks to steady sales of Dotarem®
in the US
- The X-ray segment rose by 4.2% to €94.5 million,
particularly due to the excellent performance of Optiject®
- Sales were stable in the IRT segment at €12.1 million
(+0.9%)
- The Imaging Solutions and Services (ISS) segment gained
considerable ground (+27.5%) with revenue of €20.0 million,
confirming the trend that started at the end of 2016.
Outlook
for 2017: return to growth
In less than eighteen months, the declining
sales of the business acquired at the end of 2015 were
strategically turned around. The strong performance in the 1st
quarter of 2017 for all four product segments reflects this success
achieved and gives a confidence boost to the Group, which is
confirming its full-year growth target.
Upcoming events:Publication of H1 2017
revenue July 27, 2017, after trading
About Guerbet
Guerbet is a pioneer in the contrast agent
field, with 90 years' experience, and is the only pharmaceutical
group dedicated to medical imaging worldwide. It offers a
comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and
Interventional Radiology and Theranostics (IRT) products, along
with a range of injectors and related medical devices to improve
the diagnosis and treatment of patients. To discover new products
and ensure future growth, Guerbet invests heavily in R&D,
spending around 9% of its sales each year. Guerbet (GBT) is listed
on Euronext Paris (Segment B - Mid Caps) and generated €776 million
in revenue in 2016.
For more information about Guerbet, please visit
www.guerbet.com
Contacts
Jean-François Le
MartretChief Financial Officer(+33)(0)1 45 91 50 00
|
Financial
CommunicationsBenjamin Lehari(+33)(0)1 56 88 11
25blehari@actifin.fr PressJennifer Jullia(+33)(0)1 56
88 11 19jjullia@actifin.fr |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/028a3a04-73da-440f-8851-58d53412d89b
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024